{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'The Investigator will include subjects when any of the 4 VIIS Assessment Areas have some CI', 'disease. At least 2 of the 4 VIIS Assessment Areas MUST have a scaling score of 3 or more.', 'Since for (b), (c), and (d) each include two body parts, one of each left or right must be', 'designated as the Target (upper arm, lower leg, or dorsal foot) and followed throughout the study', 'for VIIS assessment. The arm, leg, or foot with more severe and higher score will be designated', 'as the Target unless they have the same severity scores, in which case the left or right choice will', 'be at the discretion of Investigator assuming no other issues exists, dictating the choice of', 'left/right. The severity scores will be averaged by the electronic data capture system but the score', 'of two body parts that have a score of 3 or higher will be used to enroll subjects and used in', 'subsequent assessments. A five-point (0-4) scale will be used with increasing clinical severity', '(scaling) and will be defined in the training manual.', 'The primary efficacy endpoint will be the proportion of subjects with VIIS \"treatment success\"', '(VIIS-50), which is defined as a 50% or greater decrease in VIIS scaling score relative to Baseline', 'at Visit 6, End of Study (EOS) calculated using only the VIIS body areas described above that', 'have a Baseline score > 3.', 'VIIS severity will be calculated as above via one of two methods below', 'On-site visual inspection of the VIIS areas', 'Virtual/Remote visit comprised of both photographs and tele-medicine utilizing', 'synchronous video-conferencing technology. The severity score at each visit will be based', 'off information gathered from both sources to yield one score.', '4.1.2.3', \"The Investigator's Global Assessment (IGA) Assessment Area\", 'The IGA will be performed on the entire Treatment Area. The IGA assessment will inherently', 'include the VIIS Area but it will provide a broader perspective on disease status and therapeutic', 'response at baseline and subsequent visits. The IGA score is a static evaluation of the overall or', '\"average\" degree of severity of a subject\\'s disease, considering all the subject\\'s scaling and', 'fissuring in the - Treatment Areas by the Investigator or designee. This evaluation takes into', 'consideration the 2 individual characteristics of CI (scaling and fissuring) with the IGA score at', 'each visit representing the average degree of scaling and fissuring that is eligible for treatment.', 'The IGA will be assessed using the 5-point scale as shown in Table 3.', 'IGA severity will be calculated as above via one of two methods below:', 'On-site visual inspection', 'Virtual/Remote visit comprised of both photographs and tele-medicine utilizing', 'synchronous video conferencing technology. The severity score at each visit will be based', 'off information gathered from both sources to yield one score.', '22']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '4.2', 'Scientific Rationale for Study Design', 'The proposed study will use a multicenter, randomized, double-blind, parallel group,', 'vehicle-controlled study design to evaluate the efficacy and safety of 0.1% and 0.05% TMB-001', 'in the treatment of CI. The subjects will be selected according to predefined entry criteria. The', 'study treatment duration is 12 weeks and expected to be enough to show a treatment effect.', 'Isotretinoin was first approved in the US by the FDA and formulated as an oral product, Accutane', '(isotretinoin) capsules, to treat severe recalcitrant nodular acne (9). A topical formulation of', 'isotretinoin, Isotrex\u00ae (isotretinoin) gel, 0.05%, has been approved in various countries outside of', 'the US for the treatment of mild to moderate inflammatory acne vulgaris (6). The pharmacology,', 'pharmacokinetics, and toxicology of isotretinoin have been well characterized in the literature.', 'Isotretinoin is an approved active pharmacological ingredient with a long history of safe use in', 'humans under the iPLEDGE program (18). The iPLEDGE program is a risk management', 'distribution program mandated by the FDA for isotretinoin because isotretinoin must not be used', 'by female patients who are or may become pregnant. There is an extremely high risk that severe', 'birth defects will result if pregnancy occurs while taking oral isotretinoin in any amount, even for', 'a short period of time. Potentially any fetus exposed during pregnancy can be affected.', '4.3', 'Justification for Dose', 'The concentrations of TMB-001 ointment chosen for this study are based on the formulation', 'integrity and Phase 2a clinical study, specific laboratory animal toxicology studies performed by', 'the Sponsor, and a review of the published safety data for isotretinoin. The highest dose (0.2%', 'topically applied ointment) tested in the Phase 2a clinical study was reported with retinoid', 'dermatitis and lower tolerability, hence doses lower than 0.2% have been considered for this study.', 'The doses to be applied, 0.1% and 0.05%, are based upon the potential for therapeutic benefit', 'balanced with the safety risk.', '4.4', 'End of Study Definition', 'A subject is considered to have completed the study if he/she has completed the last scheduled', 'visit (Visit 6) per the Schedule of Activities (Section 1.2).', 'The end of the study is defined as the date of the last visit of the last subject in the study globally.', '23']\n\n###\n\n", "completion": "END"}